Time to initiation of therapy in oncological care is an influential factor in disease progression and survival outcomes in many cancer types. We aim to identify factors associated with delayed time to treatment (TTT) in high-grade osteosarcoma and its relationship to disease-specific survival (DSS). The SEER database was queried for biopsy-confirmed cases of high-grade osteosarcoma between 2000 and 2021 using ICD-O-3 histology codes 9180/3-9194/3 and primary site codes C40.0-41.9. χ2, Kaplan-Meier with log-rank testing, and stepwise multivariable logistic regression were completed using SPSS, with significance set to p < 0.05. Kaplan-Meier analysis demonstrated significantly reduced 5- and 10-year DSS in patients with TTT over 1 month (p < 0.001). Multivariable analysis identified advanced age groups and tumors of the cranium (aOR 2.48; 95% CI 1.96-3.13), thorax (aOR 1.72; 95% CI 1.13-2.61), and pelvis (aOR 1.71; 95% CI 1.31-2.23) as factors associated with TTT delays over 1 month. Black race and Hispanic ethnicity were also significantly associated with treatment delays in subset analysis of patients < 40 years (aOR 1.74; 95% CI 1.27-2.39 and aOR 1.31; 95% CI 1.01-1.70). These findings reveal disparities in TTT for osteosarcoma patients based on age, race/ethnicity, and tumor location, highlighting the need for equitable access to early care.
Woods et al. (Tue,) studied this question.